Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease.

ABSTRACT:

Background

Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally. External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance. The aim of this study is to characterise real-world patients according to their eligibility for guideline-cited aspirin RCTs for primary CVD prevention.

Methods

Eligibility criteria from 14 RCTs were applied to a linked primary care/hospital discharge dataset of people ≥ 40 years without CVD. Proportions eligible for each trial were calculated, and characteristics of eligible and ineligible patients compared for each trial, including Cox regression analysis of event rates for major

SUBMITTER: Holder M 

PROVIDER: S-EPMC12857110 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature